Broad neuraminidase antibodies confer protection against seasonal and avian influenza viruses.
Summary
Two human monoclonal antibodies (CAV-F6, CAV-F34) broadly inhibit neuraminidase activity, protect mice from seasonal influenza, and neutralize avian strains (H5N1, H7N9). Structural data show HCDR3 engagement of conserved active-site residues, informing NA-focused universal vaccine and therapeutic designs.
Key Findings
- Identified two monoclonal antibodies (CAV-F6, CAV-F34) that inhibit NA across multiple influenza subtypes.
- Both antibodies protected female mice from seasonal influenza and neutralized avian H5N1 and H7N9 strains.
- Structural analyses showed HCDR3-mediated binding to conserved NA active-site regions, blocking sialic acid interaction.
Clinical Implications
Supports inclusion of NA antigens in next-generation influenza vaccines and development of NA-targeting therapeutics with potential pandemic utility.
Why It Matters
This work reveals broadly neutralizing NA antibodies with activity against zoonotic strains, a key step toward universal influenza interventions beyond HA-focused strategies.
Limitations
- Protection demonstrated in mouse models; human efficacy remains to be established.
- Female mice were used for protection studies; sex-based differences were not fully explored.
Future Directions
Evaluate human prophylactic/therapeutic potential of NA bnAbs, define correlates of protection, and translate conserved NA epitopes into vaccine immunogen designs.
Study Information
- Study Type
- Case series
- Research Domain
- Prevention
- Evidence Level
- V - Preclinical mechanistic and in vivo animal studies without clinical outcomes.
- Study Design
- OTHER